Girmenia Corrado, Cimino Giuseppe, Di Cristofano Francesca, Micozzi Alessandra, Gentile Giuseppe, Martino Pietro
Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Via Benevento 6, 00161, Rome, Italy.
Support Care Cancer. 2005 Dec;13(12):987-92. doi: 10.1007/s00520-005-0783-x. Epub 2005 Mar 9.
Several studies have suggested that hydration and sodium load might reduce nephrotoxicity related to amphotericin B-deoxycholate (AmB-d). However, a schedule of these nephroprotective measures has not been standardized until now. A protocol of hydration and electrolyte supplementation was used prospectively in patients with hematological malignancies receiving empirical AmB-d treatment to evaluate its effect on AmB-d-related renal toxicity.
A total of 77 consecutive patients received AmB-d (1 mg/kg per day) in association with an initial intravenous hydration of at least 1 l/m2 body surface, containing at least 1 l of 0.9% saline daily. Hydration was increased when serum creatinine levels showed a 20% increase from baseline. Serum electrolytes were replaced when indicated.
The median duration of AmB-d therapy was 14 days. The mean intravenous hydration and the mean diuresis were 1530 and 1970 ml/m2 of body surface per day, respectively. Overall, 55 patients (71.4%) received a mean of 18.5 days of therapy without dose-limiting adverse events. Despite significant increases in mean creatinine serum levels and decreases in mean creatinine clearance observed early in the whole population, in only six patients (7.8%) was therapy discontinued due to renal failure, which always recovered after treatment discontinuation. In eight patients (10.4%) therapy was stopped due to infusion-related side effects. Seven patients died while under antifungal therapy without relevant signs of AmB-d-associated toxicity.
Our prospective experience confirms that adequate hydration (about 1500 ml/m2 of body surface) and careful electrolyte supplementation are simple measures able to contain nephrotoxicity and to permit adequate antifungal therapy at least in the empirical setting.
多项研究表明,水化和钠负荷可能会降低与两性霉素B脱氧胆酸盐(AmB-d)相关的肾毒性。然而,迄今为止,这些肾保护措施的方案尚未标准化。本研究前瞻性地采用了一种水化和补充电解质的方案,用于接受经验性AmB-d治疗的血液系统恶性肿瘤患者,以评估其对AmB-d相关肾毒性的影响。
共有77例连续患者接受AmB-d(每日1mg/kg)治疗,并初始静脉水化至少1l/m²体表面积,每日至少包含1l 0.9%生理盐水。当血清肌酐水平较基线升高20%时增加水化量。根据需要补充血清电解质。
AmB-d治疗的中位持续时间为14天。平均静脉水化量和平均尿量分别为每日1530和1970ml/m²体表面积。总体而言,55例患者(71.4%)接受了平均18.5天的治疗,无剂量限制性不良事件。尽管在整个人群中早期观察到平均血清肌酐水平显著升高和平均肌酐清除率降低,但仅有6例患者(7.8%)因肾衰竭而停药,停药后均恢复。8例患者(10.4%)因输液相关副作用停药。7例患者在抗真菌治疗期间死亡,无AmB-d相关毒性的相关体征。
我们的前瞻性经验证实,充足的水化(约1500ml/m²体表面积)和仔细的电解质补充是简单的措施,能够控制肾毒性,并至少在经验性治疗中允许进行充分的抗真菌治疗。